Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 5;129(3):295–303. doi: 10.4103/0366-6999.174489

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2016 Chinese Medical Journal

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Expression models of filaggrin and proteases involved in filaggrin processing in acute and chronic lesions of atopic dermatitis patients. Skin sections were stained for filaggrin, LEKTI, caspase14, matriptase, CAP1, KLK5, and KLK7. Filaggrin, LEKTI, and caspase14 expressions were significantly decreased, whereas matriptase, CAP1, KLK5, and KLK7 expressions were increased in AD lesions, as compared to normal controls. This phenomenon was more pronounced in the skin from patients with acute lesions (DAB staining, Original magnification ×100, the arrows point to the stained positive cells), (n = 3/three experiments in duplicate). AD: Atopic dermatitis; LEKTI: Lymphoepithelialkazal-type-related inhibitor; CAP1: Channel-activating serine protease 1; KLK5: Kallikrein 5; KLK7: Kallikrein 7.